For physicians, patients, caregivers, and researchers alike, My Cancer Genome is a resource for identifying mutations that cause cancer growth as well as therapeutics and clinical trial information. Continue reading
Catching My Eye Lately
A big merger is announced in publishing, and a nice explanation of the misinterpretations of that article on random mutations and cancer from Science. Also, some thoughts on artificial intelligence that make you go hmm, and more…
- Susan Gubar’s latest post; Living with cancer: Coming to Terms discusses the limited language surrounding cancer and has been getting some well deserved attention on social media.
- There is a big merger on the horizon in scientific publishing. It was announced on January 15 that pending approval, Nature’s parent company (Holtzbrinck Publishing Group) will essentially bring together Springer and Scientific American. The story was covered by Reuters, The NY Times, etc. Here is an item from Nature News and this is what the Springer site has to offer. I am especially interested to see how this unfolds and what it will mean for the scientific community as touched on in TeleRead.
Saying “No” to High Drug Costs and More…
- In his January 14 editorial in the NYTimes, MSK’s Dr. Peter B. Bach questioned the wisdom of legally requiring insurance companies and government programs to include coverage in their policies for all drugs, even prohibitively expensive ones, as we do in the United States. He described how just saying “no” has led to lower drug costs in other countries and even in a few cases in the US, in which a company, or in the case of MSK, a hospital, has taken a stand.
- MSK recently partnered with Enumeral Biomedical Holdings, Inc. on a two-year project supported by a $999,967 Phase II Small Business Innovation Research (SBIR) contract from the National Cancer Institute. In the project, Dr. Jedd D. Wolchok and his team will use an advanced, automated prototype system for human tissue immuno-oncology profiling developed by Enumeral.